Relapsed Chronic Lymphocytic Leukemia

Also known as: Chronic, relapsed Lymphocytic Leukemia / Relapse Chronic lymphocytic leukemia / Relapsed CLL

DrugDrug NameDrug Description
DB09054IdelalisibIdelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.
DrugDrug NamePhaseStatusCount
DB00493Cefotaxime0Recruiting1
DB00091Ciclosporin0Recruiting1
DB00531Cyclophosphamide0Recruiting1
DB01073Fludarabine0Recruiting1
DB00688Mycophenolate mofetil0Recruiting1
DB00531Cyclophosphamide1Not Yet Recruiting1
DB01073Fludarabine1Not Yet Recruiting1
DB09054Idelalisib1Not Yet Recruiting1
DB00073Rituximab1Not Yet Recruiting1
DB11581Venetoclax1Not Yet Recruiting1
DB00531Cyclophosphamide2Recruiting1
DB01073Fludarabine2Recruiting1
DB00331Metformin2Recruiting1
DB00688Mycophenolate mofetil2Recruiting1
DB00877Sirolimus2Recruiting1